Biocon Limited has acquired the remaining stake in Biocon Biologics (BBL), making it a wholly-owned subsidiary. This move simplifies the company's structure and consolidates control over its material subsidiary.

Biocon Consolidates Biocon Biologics as Wholly-Owned Subsidiary

Biocon Limited has successfully acquired the remaining stakes in its material subsidiary, Biocon Biologics Limited (BBL), through a preferential allotment. This transaction makes BBL a wholly-owned subsidiary of Biocon.

What Just Happened

Biocon acquired 1,15,36,956 shares of BBL from 127 selling shareholders, making BBL a wholly-owned subsidiary effective June 29, 2026. In exchange, Biocon allotted 87,86,362 new equity shares at an issue price of Rs 376.41 per share.

Why This Matters

This consolidation simplifies Biocon's corporate structure by eliminating minority interests at the subsidiary level. It aligns with the company's strategic goal of having complete control over its key operations.

The Backstory

Shareholders approved this preferential allotment via a postal ballot on June 7, 2026. Stock exchanges, NSE and BSE, provided their in-principle approvals on June 24, 2026.

What Changes Now

The company's issued, subscribed, and paid-up equity share capital has increased. It rose from approximately Rs 810.45 crore (1,62,09,07,773 shares) to Rs 814.85 crore (1,62,96,94,135 shares).

Investor Takeaway

Strategic consolidation achieved; corporate structure simplified. Share capital increased due to acquisition, procedural follow-through.

Context Metrics

Previous Paid-up Capital: Rs 810.45 crore (1,62,09,07,773 shares)
New Paid-up Capital: Rs 814.85 crore (1,62,96,94,135 shares)
Issue Price: Rs 376.41 per share
Acquisition Date: June 29, 2026